.39
  Price12.24%   -0.0549
(After Hours: .40 +0.0064 +1.63%)
Aug-11-22 04:22AM Marker Therapeutics Reports Q2 2022 Operating and Financial ResultsGlobeNewswire Inc.
Aug-08-22 12:49PM Why CinCor Pharma Is Trading Higher By 63%, Here Are 79 Stocks Moving In Monday's Mid-Day SessionBenzinga
06:08AM Why Is NuZee Down By Over 21%: Here Are 38 Stocks Moving PremarketBenzinga
Aug-08-22 03:05AM Why Quoin Pharmaceuticals Plunged Over 62%; Here Are 120 Biggest Movers From FridayBenzinga
Aug-05-22 03:06AM Nasdaq Falls Over 100 Points, Marker Therapeutics Shares Spike HigherBenzinga
12:53PM Why Cooper-Standard Is Trading Higher By 70%, Here Are 81 Stocks Moving In Friday's Mid-Day SessionBenzinga
Aug-05-22 12:02PM Dow Drops 150 Points, Crude Oil Rises Over 2%Benzinga
07:35AM Why Is Marker Therapeutics Trading Higher By 119%: Here Are 42 Stocks Moving PremarketBenzinga
Aug-04-22 04:37AM Marker Therapeutics Announces FDA Clearance of IND for MT-601, the six-antigen targeted T Cell Therapy for the treatment of relapsed/refractory Non-Hodgkin LymphomaGlobeNewswire Inc.
May-04-22 10:30AM Marker Therapeutics to Present Four Posters on its T Cell-Based Immunotherapies at the 2022 International Society for Cell & Gene Therapy Annual MeetingGlobeNewswire Inc.
Apr-26-22 09:04AM The Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell Therapy Trial, Fast Track Tag For Vascular Biogenics Ovarian Cancer Gene TherapyBenzinga
Mar-17-22 05:45AM Marker Therapeutics Reports Fiscal Year 2021 Operating and Financial ResultsGlobeNewswire Inc.
Mar-07-22 04:05AM Marker Therapeutics to Present at Two Upcoming March Investor ConferencesGlobeNewswire Inc.
Feb-17-22 01:08AM Why Are Marker Therapeutics Shares Trading Lower On Thursday?Benzinga
10:02AM Benzinga's Top Ratings Upgrades, Downgrades For February 17, 2022Benzinga
Feb-16-22 04:30AM Marker Therapeutics Announces Clinical Program Updates and Pipeline ExpansionGlobeNewswire Inc.
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its cell therapy technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company is also advancing various peptide- and gene-based immuno-therapeutics for the treatment of cancer and metastatic disease, including its Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and HER2/neu+ peptide antigen program (TPIV100/110) in Phase II clinical trials. In addition, it develops a proprietary DNA expression technology, known as PolyStart, to improve the ability of the cellular immune system to recognize and destroy diseased cells. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
Cap:    |  Volume (24h):